YW-N-7 TFA
YW-N-7 TFA is a PROTAC degrader targeting RET kinase, with an IC50 of 8.4 nM. YW-N-7 TFA inhibits RET kinase activity and induces proteasome-mediated degradation of RET fusion proteins, while enhancing the anti-tumor activity of Selpercatinib (LOXO-292) (HY-114370). YW-N-7 TFA can be used in the research of cancers associated with RET gene abnormalities, including medullary thyroid carcinoma, papillary thyroid carcinoma and non-small cell lung cancer.
(Pink: RET ligand (HY-170856); Blue: Cereblon E3 ligase ligand; Black: linker (HY-W086181)).
For research use only. We do not sell to patients.
- Formula: C58H63F3N12O9
- Molecular Weight:1129.19
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
RET 8.4 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| TPC1 | IC50 |
8.4 nM
|
Inhibition of RET autokinase activity in human TPC1 thyroid carcinoma cells assessed by reduced phosphorylated RET (pRET Y905) levels via immunoblotting after 24 h treatment.
Inhibition of RET autokinase activity in human TPC1 thyroid carcinoma cells assessed by reduced phosphorylated RET (pRET Y905) levels via immunoblotting after 24 h treatment.
|
39723919 |
| TPC1 | IC50 |
26.4 nM
|
Degradation of CCDC6-RET protein in human TPC1 thyroid carcinoma cells assessed by protein level analysis via immunoblotting after 24 h treatment.
Degradation of CCDC6-RET protein in human TPC1 thyroid carcinoma cells assessed by protein level analysis via immunoblotting after 24 h treatment.
|
39723919 |
In Vitro
YW-N-7 (10-1000 nM) TFA potently inhibits the proliferation of human TPC1 thyroid cancer cells and enhances the antiproliferative activity of Selpercatinib (LOXO-292) (HY-114370) in these cells[1].
YW-N-7 (200 nM; 24 h) TFA exhibits high specificity for RET in human TPC1 thyroid cancer cells[1].
YW-N-7 (0.1-500 nM; treated for 3 days in BaF3 cell line, treated for 5 hours in IMR-90 cells) TFA selectively inhibits the viability of BaF3/KIF5B-RET cells, but shows no activity against IL-3-dependent BaF3 cells, VEGFR2-dependent BaF3/TEL-VEGFR2 cells, or normal IMR-90 human diploid fibroblasts[1].
YW-N-7 (50-250 nM; 15 h) TFA inhibits RET kinase activity and degrades KIF5B-RET protein in BaF3/KIF5B-RET cells[1].
YW-N-7 (0.1-500 nM; 3 days) TFA potently inhibits the proliferation of BaF3/KIF5B-RET cells[1].
YW-N-7 (TFA) (200 nM; 24 h) significantly reduces RET protein abundance in CCDC6-RET fusion-positive TPC1 thyroid cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human TPC1 thyroid carcinoma cells (CCDC6-RET fusion-positive)
-
Concentration:0.5, 1, 5, 10, 25, 50, 100 nM (24 h); 50, 250 nM (3, 6, 9, 24, 48 h)
-
Incubation Time:3, 6, 9, 24, 48 h
-
Result:Inhibited RET kinase activity and degraded CCDC6-RET protein in a dose-dependent manner.
Reduced CCDC6-RET protein with a half-life of 2 h at 50 nM, reaching a maximal 97.3% reduction at 9 h, and maintaining 93.5% reduction at 24 h.
Reduced CCDC6-RET protein with a half-life of 5 h at 250 nM, with a maximal 88% reduction at 9 h.
Prevented CCDC6-RET degradation but retained kinase inhibition when cotreated with excess LOXO-292 or lenalidomide.
Blocked CCDC6-RET degradation but still inhibited kinase activity when cotreated with bortezomib.
Exhibited an IC50 of 8.4 nM for RET autokinase inhibition and an IC50 of 26.4 nM for CCDC6-RET degradation.
-
Cell Line:BaF3/KIF5B-RET (B/KR) cells
-
Concentration:50, 100, 250 nM
-
Incubation Time:15 h
-
Result:Inhibited RET kinase activity (reduced pRET Y905 levels) in a dose-dependent manner.
Degraded KIF5B-RET protein in a dose-dependent manner.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SHO (female, 6-week-old)[1]
-
Dosage:100 mg/kg; 150 mg/kg
-
Administration:i.p.; once daily (Day 9 start for 100 mg/kg; Day 17 start for 150 mg/kg)
-
Result:Significantly inhibited tumor growth compared to vehicle control.
Reduced tumor size at study end point compared to vehicle control.
Decreased levels of active Tyr-905-phosphorylated KIF5B-RET and total KIF5B-RET protein in tumor samples.
Did not reduce animal body weight at either dose.
Chemical Information
-
Molecular Weight 1129.19
-
Formula C58H63F3N12O9
-
SMILES
O=C(C1=CN=C(C=C1)N2CCN(CC2)C(CCCCCCCOC3=CN4C(C(C5=CC=C(N=C5)N6CC7CC(C6)N7CC8=CC=C(N=C8)OC)=C3)=C(C=N4)C#N)=O)NCCOC9=CC=C(C=C9)C(C(N%10)=O)CCC%10=O.O=C(O)C(F)(F)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)